GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice.
Arai, Sawako a,1; Takuma, Kazuhiro a,1; Mizoguchi, Hiroyuki a,b; Ibi, Daisuke a; Nagai, Taku c; Kamei, Hiroyuki d; Kim, Hyoung-Chun e; Yamada, Kiyofumi a,c,f,*
[Miscellaneous Article] European Journal of Pharmacology. 602(1):101-104, January 5, 2009.

(Format: HTML, PDF)

In this study, we investigated the effects of GABAA and GABAB receptor agonists on the methamphetamine-induced impairment of recognition memory in mice. Repeated treatment with methamphetamine at a dose of 1 mg/kg for 7 days induced an impairment of recognition memory. Baclofen, a GABAB receptor agonist, ameliorated the repeated methamphetamine-induced cognitive impairment, although gaboxadol, a GABAA receptor agonist, had no significant effect. GABAB receptors may constitute a putative new target in treating cognitive deficits in patients suffering from schizophrenia, as well as methamphetamine psychosis.

(C) 2009Elsevier, Inc.